Bio-Rad Laboratories (BIO) Receivables (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Receivables data on file, last reported at $439.5 million in Q1 2026.

• Receivables for Q1 2026 came in at $439.5 million, changed 0.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $439.5 million (changed 0.25% YoY), and the FY2025 annual result was $472.5 million, up 1.48% from the prior year.
• Receivables eased to $439.5 million in Q1 2026 per BIO's latest filing, from $472.5 million in the prior quarter.
• Over five years, Receivables peaked at $513.1 million in Q1 2023 and troughed at $438.4 million in Q1 2025.
• A 5-year average of $471.4 million and a median of $470.7 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2024: Receivables gained 18.91% in 2022, then decreased 10.42% in 2024.
• A 5-year view of Receivables shows it stood at $506.2 million in 2022, then decreased by 1.06% to $500.9 million in 2023, then dropped by 7.05% to $465.6 million in 2024, then gained by 1.48% to $472.5 million in 2025, then slipped by 6.98% to $439.5 million in 2026.
• Business Quant data shows BIO's Receivables at $439.5 million in Q1 2026, $472.5 million in Q4 2025, and $474.2 million in Q3 2025.